A carregar...
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
SIMPLE SUMMARY: Patients with chronic lymphocytic leukemia (CLL), the most frequent B cell malignancy in western countries, develop a progressive immunosuppression, leading to diminished anti-tumor immunity. Within the last years, immune checkpoint blockade has revolutionized anti-cancer therapies....
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8123840/ https://ncbi.nlm.nih.gov/pubmed/33925565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13092112 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|